Depending on the tumor localization, it is possible to target different candidate proteins, generally transmembrane receptors or releasing hormone receptors, with theranostic performances useful in understanding cancer progression and improving treatment efficacy (Gulfidan et al., 2020). This evidence concerns the gene NRP1 and cancer.